Navigation Links
PINC trial launched to test new treatment for pre-invasive breast cancer
Date:3/2/2010

standard of care surgery to treat their DCIS disease. We believe that the treatment will kill the DCIS cells before they become invasive and shrink the size of the DCIS. We may be able to prevent someone from needing a mastectomy and offer them breast conserving surgery."

Once patients have consented and enrolled, the size of their breast tumor will be measured through a non-invasive imaging technique called magnetic resonance imaging (MRI). Tissue samples will be taken from patients by Inova's doctors and transported to CAPMM for analysis. The PINC trial will combine chloroquine with Tamoxifen depending on the patient's tumor profile. After treatment, the MRI will be repeated to see if the tumor has shrunk and the patient will then proceed with surgery and follow up therapy.

What made the researchers think to use a malaria drug to treat breast cancer? According to Ginny Espina, a CAPMM research assistant professor, it works by starving the cancerous cells.

"Pre-cancerous cells have adapted to survive inside the milk duct without a blood supply and with very few nutrients. They overcome starvation through a process called autophagy. It's a way for a cell to make its own food and store it in a 'cookie jar.' In the breast ducts, the DCIS cells use these 'cookies' to survive and potentially spread. Simply put, chloroquine goes into the cell's 'cookie jars' and prevents the cells from using that food so that they eventually die from starvation," says Espina.

Of note, researchers are also using chloroquine in patients with unique types of brain tumors.

The treatment of DCIS is controversial because most DCIS lesions remain dormant and do not become invasive. Physicians do not want to over treat DCIS and cause unnecessary side effects if the DCIS does not become aggressive. However, chloroquine is a relatively safe treatment that does not have the severe side effects of typical chemotherapy.

"I think the most exciting
'/>"/>

Contact: Marjorie Musick
mmusick@gmu.edu
703-993-8781
George Mason University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Heart Pump Shows Promise in Trial
2. Trial to Test Gene Therapy for Angina in Women
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. MDS Pharma Services Wins Award for Management of Global Malaria Trial
7. New Ovarian Cancer Drug Trial Under Way
8. Study Questions Dead-End Cancer Clinical Trials
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
11. Clinical trials present better alternatives for dialysis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) filed ... strokes and other serious cardiovascular events due to their ... forward in the federal multidistrict litigation now underway in ... a Case Management Order issued on March 3rd, the ... master pleadings in the proceeding. Among other things, the ...
(Date:3/5/2015)... 2015 On March 2, 2015, NBC ... on the Rise, Plastic Surgeons Say,” that comments on ... for Aesthetic Plastic Surgery and the American ... a year-over-year doubling of surgical butt augmentations performed in ... the article, this increase can be attributed to the ...
(Date:3/5/2015)... HMP Communications Holdings , ... education, announced today its acquisition of the ... medical conference designed for health care providers dedicated ... amputation due to vascular disorders. The 5-year-old ... publications and CME activities across therapeutic fields such ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... 2015 Leading nutritional supplement provider ... Sports Festival and Arnold Fitness EXPO in ... will host a display booth featuring free samples of ... its highly-popular, class-leading fat burner Synedrex. The company will ... that utilize its top-of-the-line supplements and miniature action figures ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2
... test by using EEG can predict whether a person ... by Leslie S. Prichep of the New York University School ... 44 patients and followed these people for a decade. The ... would develop dementia. ,Dementia is a brain disorder that causes ...
... research from the National Institute of Diabetes and Digestive and ... shown stabalisation of annual increases from 5 to 10 ... there is still a dramatic racial disparity. , ... than 1 percent since 1999, compared to an average 5 ...
... cancer vaccine trial against Melanoma which is a type ... vaccine developed by Antigenics.// The vaccine trial of Oncophage ... the required statistically significance results compared to prolongation in ... any better results compared to other cancer treatments. ...
... a near-pandemic condition that threatens millions with loss of ... atherosclerotic plaque in the arteries outside your heart.// Stem ... blood vessels and grow new ones thus restoring blood ... Ltd, a private, multinational company focuses on using stem ...
... inflammation according to scientists. Inflammation has a role to ... cardiovascular disease, diabetes, obesity, Alzheimer’s besides infections//. , ... said: “Practically every common disease involves an inflammation component,” ... Research (SFBR) in San Antonio., ,“So the discovery ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
Cached Medicine News:Health News:US Kidney Failure Rates show Stabilization After 20-Year Climb 2Health News:Tennis elbow not new among cricketers, say experts 2
(Date:3/5/2015)... EDISON, N.J. , March 5, 2015  ContraVir ... company focused on the development and commercialization of targeted ... the 27 th Annual ROTH Conference, to be ... CA. James Sapirstein , ... Company,s business during his live presentation and will be ...
(Date:3/5/2015)... March 5, 2015 According to ... by Product (Systems and Disposables), by Type (Invasive, Minimally ... Home and Ambulatory Sites) - Analysis & Global Forecast ... is expected to reach $1,107.4 Million by 2019 from ... at a CAGR of 4.5% during the forecast period. ...
(Date:3/5/2015)... Denmark , March 5, 2015 ... that applies its innovative TransCon technology to address ... present two posters at the ENDO 2015 conference ... The posters will be presented on Thursday, March ... is being held from 1:00pm-3:00pm PST, and are ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4Ascendis Pharma to Present at ENDO 2015 2
... Worldwide, MENLO PARK, Calif., Nov. 15 ... global Phase III clinical program to,evaluate the efficacy ... program, which includes the COGENT-1 and COGENT-2 trials, ... in the United States, Canada,Europe and South America. ...
... Calif., Nov. 15 BiPar,Sciences, Inc., a privately ... it has initiated a Phase 2 study of ... breast,cancer that do not express the estrogen, progesterone ... Phase 2 trial in this indication-which,represents a major ...
Cached Medicine Technology:Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
... four models in proven halogen technology and ... find the right solution for every application: ... combination of two or three mobile lamps ... an on/off switch on the lamp housing, ...
Advanced Lighting System with Multi-Lamp Design providing Surgeon Focus Control and Extended, Variable Depth of Field over greater working distances. High Intensity, Cool Beam Temperature...
Medicine Products: